Making regenerative medicine a part of everyday medicine
Cook MyoSite is leading the pursuit of muscle-derived cell therapies to solve unmet needs in mainstream indications


Our story is a human story
Cook MyoSite, Inc., a subsidiary of the Cook Group, was established in 2002 to pioneer advancements in cellular technologies. Driven by a belief in the human body's restorative abilities, Cook MyoSite leverages extensive expertise in muscle-derived cell technology for therapeutic applications.
Our commitment to innovation, quality, and scientific exploration has propelled the development and delivery of autologous muscle-derived cell (AMDC) technologies, now under investigation in leading clinical trials for various medical uses. We partner with researchers and companies across the globe, offering insights, products, and services to support research in human muscle cell applications. For more than 20 years, our team has been dedicated to overcoming scientific boundaries, championing the body's healing capabilities, and enabling individuals to harness their own muscles for recovery.




Our story is a human story
Cook MyoSite, Inc., a subsidiary of the Cook Group, was established in 2002 to pioneer advancements in cellular technologies. Driven by a belief in the human body's restorative abilities, Cook MyoSite leverages extensive expertise in muscle-derived cell technology for therapeutic applications.
Our commitment to innovation, quality, and scientific exploration has propelled the development and delivery of autologous muscle-derived cell (AMDC) technologies, now under investigation in leading clinical trials for various medical uses. We partner with researchers and companies across the globe, offering insights, products, and services to support research in human muscle cell applications. For more than 20 years, our team has been dedicated to overcoming scientific boundaries, championing the body's healing capabilities, and enabling individuals to harness their own muscles for recovery.

Our Leaders

Carl Cook earned his bachelor’s degree in electrical engineering from Purdue University and his MBA from the University of Iowa. Carl joined Cook Group in 1988, founded by his father, Bill Cook. Si...
Ron Jankowski has been with Cook MyoSite since its founding and has more than 20 years of experience in translational medical and biologic product development. He earned his bachelor’s degree in ch...
Ryan Pruchnic earned his bachelor’s degree in biology and his master’s degree in exercise physiology from the University of Pittsburgh and his MBA from the Joseph M. Katz Graduate School of Busines...

Carl Cook earned his bachelor’s degree in electrical engineering from Purdue University and his MBA from the University of Iowa. Carl joined Cook Group in 1988, founded by his father, Bill Cook. Since then, Carl Cook has performed a variety of duties, including engineering cardiac pacemakers and Doppler blood flow monitors and working with endoscopy products. Most recently, Carl Cook serves as the CEO of Cook Group and the President of Cook MyoSite, Inc.

Ron Jankowski has been with Cook MyoSite since its founding and has more than 20 years of experience in translational medical and biologic product development. He earned his bachelor’s degree in chemical engineering, master’s degree in bioengineering, and doctoral degree in bioengineering from the University of Pittsburgh. He leads the regulatory affairs, process development and clinical development programs for the company's therapeutic products. He is also actively involved in the local life science community through promotion of innovation, entrepreneurism, and workforce development.

Ryan Pruchnic earned his bachelor’s degree in biology and his master’s degree in exercise physiology from the University of Pittsburgh and his MBA from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. While working as a research scientist investigating the experimental uses of skeletal muscle-derived cells for urinary tract tissue augmentation, he was part of the original team that custom-built the cell isolation and manufacturing technology for use in human clinical trials. Ryan has authored and co-authored numerous peer-reviewed scientific journal articles and book chapters relating to gene and cell therapy research for musculoskeletal disorders. Ryan currently serves as Site Head for Cook MyoSite and is responsible for the Manufacturing and Business Administration functions of the company.
Our Journey
2002
Cook MyoSite is formed.
2004
2007
2013
2017
As clinical trials expand, Cook MyoSite opens a new facility across the street at 100 Delta Drive. The company begins producing cell products for two physician-sponsored studies investigating AMDC technology:
• Phase I/II study for underactive bladder
• Phase I/II study for tongue dysphagia
2020
Phase I/II underactive bladder clinical trial is completed. The FDA grants the RMAT designation to iltamiocel for the female stress urinary incontinence indication, and recruitment begins for the second Phase III study, known as the CELLEBRATE study.
2022
2024
The first participant in Cook MyoSite's fecal incontinence trial, known as DigniFI, receives an iltamiocel injection. The FDA grants a third RMAT designation to iltamiocel, this time for the oropharyngeal dysphagia indication.
2025

CAREERS
Discover what’s Humanly Possible at Cook MyoSite
Cook MyoSite is at the forefront of groundbreaking advancements in the medical field, venturing into uncharted territories of scientific discovery and technological innovation. At the core of our philosophy lies a profound belief in the vast, untapped potential within our groundbreaking technologies and within the human body itself.
We hold an unwavering belief that every individual who joins our organization has the potential to conceive and develop revolutionary ideas capable of reshaping the world as we know it. It is precisely this conviction that has driven us to cultivate a diverse workplace powered by an entrepreneurial spirit where each team member is genuinely valued and recognized for the integral role they play in advancing our mission.
Our small company tackles big challenges, aiming to unlock the potential in our technologies and the human body. If you're ready to push the boundaries of what's humanly possible, join us.